February 8, 2010 – Daiichi Sankyo Company, Limited, announced that its subsidiary, ASUBIO PHARMA CO., LTD. , submitted a New Drug Application in Japan for the manufacturing and marketing of SUN Y7017 (generic name: Memantine hydrocholoride), which was developed for the treatment of Alzheimer’s type Dementia (AD).
SUN Y7017 is an N-methyl-D-aspartate (NMDA) receptor antagonist developed by Merz Pharmaceuticals GmbH... [PDF] Daiichi Sankyo's Press Release -
February 8, 2010 - KineMed, Inc. a translational and personalized medicine development company, announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimer’s disease and other neurodegenerative conditions. This agreement builds on the original collaboration between the two companies begun in June 2009.
“We are very pleased to be working with Bristol Myers Squibb to enable the development of their drugs intended to slow the progression of Alzheimer’s disease by novel mechanisms. KineMed is excited by the possibility that our novel measures of brain function could play a crucial role in advancing such potentially beneficial new medicines... KineMed's Press Release -
January 20, 2010 - Pharma major, Lupin Ltd announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received the tentative approval for the Company’s Abbreviated New Drug Application (ANDA) for its Memantine Hydrochloride tablets, 5mg and 10mg from the US Food and Drug Administration (US FDA).
January 20, 2010 – DiaGenic ASA (OSL:DIAG) and Ferrer inCode announced that they have signed a distribution agreement for the blood-based ADtect® test for early diagnosis of Alzheimer’s disease covering a total of 32 countries. The agreement gives Ferrer inCode, a biotech subsidiary of Grupo Ferrer Internacional, the exclusive right to sell and market ADtect® initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy, Spain and Portugal followed by Latin America.
06 Jan,2010 - Pharmaceutical and biotechnology major Wockhardt has received tentative approval from the United States Food & Drug Administration (US FDA) for marketing the 5mg and 10mg tablets of Memantine HCl, which is used for treatment of moderate to severe Alzheimer’s disease and dementia. Memantine is the generic name for the brand Namenda, marketed in the United States by Forrest Laboratories. The patent covering this product is under litigation in the US courts. Wockhardt and Forrest Laboratories have reached a settlement on their patent litigation, which will allow Wockhardt to launch its generic version several months ahead of patent expiration or as soon as any other generic version is launched. According to IMS, the total market for Memantine tablets in the US is about $1.1 billion and is the first in a novel class of Alzheimer’s drugs that block NMDA glutamate receptors... Wockhardt's Press Release -
July 15, 2009 – Cognition Therapeutics Inc., a Pittsburgh-based drug discovery company developing small molecule disease-modifying treatments for Alzheimer’s, has closed on a $1.21M Series A financing. The round was led by Ogden CAP, LLC of New York City and includes M5Invest Partners of Villanova, PA, the Pittsburgh Life Sciences Greenhouse, Innovation Works (Pittsburgh), and several individual investors. The round included both new investments and the conversion of existing convertible notes.
3 November, 2009: The European Commission and the US Food and Drug Administration (FDA) have granted Noscira, a biotechnology subsidiary of Grupo Zeltia (ZEL.MC), orphan drug status for Nypta® (NP-12) for treating Progressive Supranuclear Palsy (PSP), a neurodegenerative disease...
March 9, 2009 - ProteoTech Inc. announced that both Dr. Alan D. Snow, Chairman, President & CSO, and Dr. Luke Esposito, Director of In Vitro Screening, will present at the 9th International Conference for Alzheimer’s and Parkinson’s Diseases, to be held in Prague, Czech Republic, March 11-15, 2009. On Sunday March 15, Dr. Alan D. Snow will give an oral presentation discussing promising results pertaining to ProteoTech’s current Phase 1A human clinical trial with the small molecule Exebryl-1® for the treatment of mild-to-moderate Alzheimer’s disease. Dr. Snow’s talk is entitled: “Exebryl-1®: A Novel Small Molecule Currently in Human Clinical Trials as a Disease-Modifying Drug for the Treatment of Alzheimer’s Disease.”... [PDF] ProteoTech's Press Release -
